Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Gainesville, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Miami, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Pensacola, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Columbus, GA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Nampa, ID
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Nampa, ID
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Hutchinson, KA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Hutchinson, KA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Topeka, KA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Lebanon, NH
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Durham, NC
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Mayfield Heights, OH
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Greenville, SC
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Alcoa, TN
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Alcoa, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site 1
mi
from
Austin, TX
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site 1
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Fort Sam Houston, TX
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Madison, WI
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Milwaukee, WI
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Hobart,
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Hobart,
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Metairie, LA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Saint Paul, MN
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Saint George, UT
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Saint George, UT
Click here to add this to my saved trials
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated:  12/31/1969
University of Michigan/ CS Mott Children's Hospital
mi
from
Ann Arbor, MI
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK
Status: Enrolling
Updated: 12/31/1969
University of Michigan/ CS Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Hradec Kralove,
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Hradec Kralove,
Click here to add this to my saved trials
Skin Prep to Reduce Postoperative Shoulder Infection
Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection
Status: Enrolling
Updated:  12/31/1969
University of Maryland Midtown Hospital
mi
from
Baltimore, MD
Skin Prep to Reduce Postoperative Shoulder Infection
Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection
Status: Enrolling
Updated: 12/31/1969
University of Maryland Midtown Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn
IGHID 11519 - Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Jaycee Burn Center
mi
from
Chapel Hill, NC
Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn
IGHID 11519 - Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Jaycee Burn Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Status: Enrolling
Updated:  12/31/1969
University Hospital Essen
mi
from
Essen,
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Longitudinal Gene Expression Profiling in Adults After Traumatic Injury
Status: Enrolling
Updated: 12/31/1969
University Hospital Essen
mi
from
Essen,
Click here to add this to my saved trials
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Status: Enrolling
Updated:  12/31/1969
CTE Forecariah
mi
from
Forecariah,
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Status: Enrolling
Updated: 12/31/1969
CTE Forecariah
mi
from
Forecariah,
Click here to add this to my saved trials
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor
Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix
mi
from
Phoenix, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Scottsdale - Infectious Diseases
mi
from
Scottsdale, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Scottsdale - Infectious Diseases
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson
mi
from
Tucson, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Chester Avenue Medical Offices - Pulmonology
mi
from
Bakersfield, CA
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Chester Avenue Medical Offices - Pulmonology
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Kern Medical Center - Medicine
mi
from
Bakersfield, CA
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Kern Medical Center - Medicine
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases
mi
from
Lancaster, CA
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases
mi
from
Lancaster, CA
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
St Josephs Hospital and Medical Center - Center for Liver Disease and Transplantation - Phoenix
mi
from
Phoenix, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
St Josephs Hospital and Medical Center - Center for Liver Disease and Transplantation - Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
UCSF Fresno Center for Medical Education and Research - Clinical Research Center
mi
from
Fresno, CA
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
UCSF Fresno Center for Medical Education and Research - Clinical Research Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Phoenix - Infectious Diseases
mi
from
Phoenix, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Phoenix - Infectious Diseases
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated:  12/31/1969
Biomat Lincoln
mi
from
Lincoln, NE
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated: 12/31/1969
Biomat Lincoln
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated:  12/31/1969
Biomat Bellflower
mi
from
Bellflower, CA
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated: 12/31/1969
Biomat Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated:  12/31/1969
Biomat Clarksville
mi
from
Clarksville, TN
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated: 12/31/1969
Biomat Clarksville
mi
from
Clarksville, TN
Click here to add this to my saved trials
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated:  12/31/1969
Biomat Salt Lake City 1
mi
from
Salt Lake City, UT
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program
Status: Enrolling
Updated: 12/31/1969
Biomat Salt Lake City 1
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Rockland Division of Highland Medical PC
mi
from
Nyack, NY
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Rockland Division of Highland Medical PC
mi
from
Nyack, NY
Click here to add this to my saved trials